ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

BACKGROUND: Patients with metastatic colorectal cancer whose disease has progressed on oxaliplatin- and irinotecan-containing regimens may benefit from EGFR-inhibiting monoclonal antibodies if they do not contain mutations in the KRAS gene (are “wild type”). It is unknown whether these antibodies, s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Segelov, Eva, Waring, Paul, Desai, Jayesh, Wilson, Kate, Gebski, Val, Thavaneswaran, Subotheni, Elez, Elena, Underhill, Craig, Pavlakis, Nick, Chantrill, Lorraine, Nott, Louise, Jefford, Michael, Khasraw, Mustafa, Day, Fiona, Wasan, Harpreet, Ciardiello, Fortunato, Karapetis, Chris, Joubert, Warren, van Hazel, Guy, Haydon, Andrew, Price, Tim, Tejpar, Sabine, Tebbutt, Niall, Shapiro, Jeremy
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4886432/
https://ncbi.nlm.nih.gov/pubmed/27246726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2389-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados